Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 24 | 2024 | 328 | 7.360 |
Why?
|
| Arthralgia | 10 | 2023 | 132 | 4.090 |
Why?
|
| Osteoarthritis, Knee | 9 | 2023 | 361 | 3.310 |
Why?
|
| Pain | 15 | 2024 | 382 | 3.250 |
Why?
|
| Nociceptors | 6 | 2023 | 20 | 2.700 |
Why?
|
| Hyperalgesia | 8 | 2024 | 46 | 2.370 |
Why?
|
| Ganglia, Spinal | 12 | 2024 | 58 | 2.360 |
Why?
|
| Animals | 38 | 2024 | 3330 | 2.350 |
Why?
|
| Mice | 26 | 2024 | 1296 | 2.060 |
Why?
|
| Arthritis, Experimental | 6 | 2020 | 47 | 2.000 |
Why?
|
| Disease Models, Animal | 20 | 2024 | 560 | 1.870 |
Why?
|
| Receptors, CCR2 | 4 | 2021 | 10 | 1.370 |
Why?
|
| Neurons | 3 | 2017 | 326 | 1.320 |
Why?
|
| Immunity, Innate | 3 | 2020 | 59 | 1.300 |
Why?
|
| Nerve Growth Factor | 3 | 2024 | 43 | 1.290 |
Why?
|
| Knee Joint | 5 | 2024 | 744 | 1.290 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 398 | 1.280 |
Why?
|
| Cartilage, Articular | 6 | 2018 | 416 | 1.040 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 210 | 1.040 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 20 | 0.980 |
Why?
|
| Macrophages | 2 | 2024 | 93 | 0.970 |
Why?
|
| Neuroimmunomodulation | 3 | 2020 | 9 | 0.970 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 59 | 0.940 |
Why?
|
| Microscopy | 1 | 2024 | 11 | 0.910 |
Why?
|
| Chronic Pain | 5 | 2022 | 129 | 0.890 |
Why?
|
| Peptides | 3 | 2014 | 96 | 0.890 |
Why?
|
| Synovitis | 2 | 2022 | 22 | 0.840 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 192 | 0.830 |
Why?
|
| Nociception | 4 | 2019 | 10 | 0.790 |
Why?
|
| Behavior, Animal | 2 | 2024 | 47 | 0.770 |
Why?
|
| Male | 18 | 2024 | 13669 | 0.740 |
Why?
|
| Tissue Engineering | 2 | 2011 | 31 | 0.700 |
Why?
|
| Calcium | 3 | 2018 | 334 | 0.680 |
Why?
|
| Gene Expression | 2 | 2020 | 196 | 0.640 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 15 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 160 | 0.630 |
Why?
|
| Pain Management | 2 | 2018 | 140 | 0.630 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 61 | 0.630 |
Why?
|
| Aggrecans | 2 | 2018 | 52 | 0.600 |
Why?
|
| Humans | 26 | 2023 | 24703 | 0.600 |
Why?
|
| Mice, Knockout | 6 | 2023 | 290 | 0.590 |
Why?
|
| ADAM Proteins | 2 | 2015 | 40 | 0.590 |
Why?
|
| Cytokines | 3 | 2019 | 218 | 0.590 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 34 | 0.570 |
Why?
|
| Cannabinoids | 1 | 2017 | 3 | 0.560 |
Why?
|
| Phytotherapy | 1 | 2017 | 11 | 0.560 |
Why?
|
| Cannabis | 1 | 2017 | 10 | 0.550 |
Why?
|
| Clozapine | 1 | 2017 | 5 | 0.550 |
Why?
|
| Neural Inhibition | 1 | 2017 | 7 | 0.550 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2023 | 27 | 0.530 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 17 | 0.530 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 305 | 0.500 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 16 | 0.480 |
Why?
|
| Stifle | 1 | 2015 | 10 | 0.480 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 19 | 0.450 |
Why?
|
| Tissue Scaffolds | 2 | 2011 | 26 | 0.450 |
Why?
|
| Joints | 1 | 2014 | 68 | 0.430 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 8 | 0.420 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 6 | 0.420 |
Why?
|
| Menisci, Tibial | 4 | 2020 | 173 | 0.410 |
Why?
|
| Drug Carriers | 1 | 2011 | 6 | 0.370 |
Why?
|
| Blood Coagulation | 3 | 2006 | 20 | 0.370 |
Why?
|
| Heparin | 2 | 2010 | 21 | 0.370 |
Why?
|
| Nerve Growth Factors | 2 | 2023 | 37 | 0.360 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2021 | 9 | 0.360 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 310 | 0.360 |
Why?
|
| Female | 8 | 2024 | 14048 | 0.360 |
Why?
|
| Chondroitin Sulfates | 1 | 2010 | 6 | 0.350 |
Why?
|
| Chondrogenesis | 1 | 2010 | 31 | 0.340 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 30 | 0.330 |
Why?
|
| Plasma | 2 | 2006 | 15 | 0.310 |
Why?
|
| Cells, Cultured | 4 | 2015 | 492 | 0.300 |
Why?
|
| RNA, Messenger | 3 | 2023 | 294 | 0.290 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 55 | 0.280 |
Why?
|
| Disease Progression | 2 | 2020 | 632 | 0.270 |
Why?
|
| Synovial Membrane | 3 | 2022 | 54 | 0.270 |
Why?
|
| ADAMTS5 Protein | 2 | 2018 | 21 | 0.270 |
Why?
|
| Signal Transduction | 3 | 2023 | 413 | 0.260 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 40 | 0.240 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 348 | 0.230 |
Why?
|
| Models, Theoretical | 3 | 2020 | 78 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 193 | 0.230 |
Why?
|
| Immunophenotyping | 1 | 2023 | 26 | 0.210 |
Why?
|
| Hydrogels | 3 | 2014 | 7 | 0.210 |
Why?
|
| Cattle | 3 | 2014 | 118 | 0.200 |
Why?
|
| Ion Channels | 1 | 2023 | 118 | 0.190 |
Why?
|
| Analgesics | 2 | 2020 | 79 | 0.190 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 12 | 0.190 |
Why?
|
| Chondrocytes | 2 | 2014 | 154 | 0.190 |
Why?
|
| Skin Abnormalities | 1 | 2021 | 2 | 0.190 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 8 | 0.190 |
Why?
|
| Infant | 1 | 2023 | 482 | 0.180 |
Why?
|
| Sensory Receptor Cells | 1 | 2021 | 9 | 0.180 |
Why?
|
| Bone Marrow Cells | 2 | 2011 | 53 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 113 | 0.170 |
Why?
|
| Radiography | 2 | 2014 | 611 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 122 | 0.170 |
Why?
|
| Microarray Analysis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 20 | 0.160 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 5 | 0.160 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 7 | 0.160 |
Why?
|
| Alarmins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Biomarkers | 2 | 2019 | 520 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 128 | 0.160 |
Why?
|
| Phenotype | 1 | 2020 | 280 | 0.150 |
Why?
|
| Rats | 2 | 2018 | 609 | 0.150 |
Why?
|
| ADAMTS4 Protein | 1 | 2018 | 15 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 18 | 0.140 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 6 | 0.140 |
Why?
|
| Random Allocation | 2 | 2016 | 121 | 0.140 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 3 | 0.140 |
Why?
|
| TRPC Cation Channels | 1 | 2017 | 4 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 7 | 0.140 |
Why?
|
| Dronabinol | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cannabidiol | 1 | 2017 | 3 | 0.140 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 7 | 0.140 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 6 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 312 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 24 | 0.140 |
Why?
|
| Joint Instability | 1 | 2021 | 394 | 0.140 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 72 | 0.140 |
Why?
|
| Catalysis | 3 | 2013 | 16 | 0.140 |
Why?
|
| Chemokines, CC | 1 | 2017 | 3 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2017 | 68 | 0.130 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 2 | 2014 | 3 | 0.130 |
Why?
|
| Osteonecrosis | 1 | 2017 | 16 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 26 | 0.130 |
Why?
|
| Drug Design | 2 | 2014 | 22 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 75 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 79 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 708 | 0.120 |
Why?
|
| Calgranulin A | 1 | 2015 | 5 | 0.120 |
Why?
|
| alpha-Macroglobulins | 1 | 2015 | 13 | 0.120 |
Why?
|
| Pain Measurement | 1 | 2018 | 467 | 0.120 |
Why?
|
| Adsorption | 2 | 2014 | 5 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 8 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 13 | 0.120 |
Why?
|
| Microglia | 1 | 2016 | 130 | 0.120 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 2 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 28 | 0.110 |
Why?
|
| Horses | 1 | 2014 | 10 | 0.110 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 86 | 0.110 |
Why?
|
| Dogs | 1 | 2014 | 147 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2015 | 173 | 0.110 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 19 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 32 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 630 | 0.100 |
Why?
|
| Biotinylation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Streptavidin | 1 | 2011 | 3 | 0.090 |
Why?
|
| Fluorometry | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 7 | 0.090 |
Why?
|
| Glycosaminoglycans | 1 | 2011 | 20 | 0.090 |
Why?
|
| Solubility | 1 | 2011 | 25 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2011 | 56 | 0.090 |
Why?
|
| DNA | 1 | 2011 | 97 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2011 | 33 | 0.090 |
Why?
|
| Kinetics | 1 | 2011 | 149 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 129 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 3 | 0.090 |
Why?
|
| Polysaccharide-Lyases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Regeneration | 1 | 2010 | 17 | 0.090 |
Why?
|
| Models, Animal | 1 | 2010 | 108 | 0.090 |
Why?
|
| Lipopolysaccharides | 2 | 2023 | 91 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 33 | 0.080 |
Why?
|
| Injections, Intra-Articular | 1 | 2010 | 86 | 0.080 |
Why?
|
| Rabbits | 1 | 2010 | 178 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Surface Properties | 2 | 2006 | 129 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2008 | 4 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 50 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 284 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 307 | 0.070 |
Why?
|
| Silanes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 4 | 0.060 |
Why?
|
| Arthroscopy | 1 | 2014 | 1095 | 0.060 |
Why?
|
| Factor XII | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Coagulants | 1 | 2005 | 11 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 88 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 35 | 0.050 |
Why?
|
| Mitochondria | 1 | 2022 | 56 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2022 | 96 | 0.050 |
Why?
|
| Collagen Type V | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 437 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 258 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 116 | 0.040 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 6 | 0.040 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2017 | 1 | 0.040 |
Why?
|
| Piperidines | 1 | 2017 | 12 | 0.040 |
Why?
|
| Indoles | 1 | 2017 | 31 | 0.030 |
Why?
|
| Podocytes | 1 | 2017 | 37 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 8382 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 37 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 132 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 174 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 32 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 56 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 37 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 3 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 22 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 112 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 174 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 121 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 169 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2014 | 167 | 0.030 |
Why?
|
| Brain | 1 | 2017 | 1539 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2008 | 8 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 27 | 0.020 |
Why?
|
| Binding Sites | 1 | 2008 | 62 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 110 | 0.020 |
Why?
|
| Factor XIIa | 1 | 2005 | 1 | 0.020 |
Why?
|
| Titrimetry | 1 | 2005 | 3 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 7255 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2005 | 35 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 12 | 0.010 |
Why?
|
| Thrombin | 1 | 2005 | 15 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 19 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 8294 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 123 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1327 | 0.010 |
Why?
|